Superworth

Galectin Therapeutics EPS GALT

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$0.44
Latest quarter, Q2 FY26
−$0.14
Fiscal year 2025
−$0.49

Galectin Therapeutics' earnings per share was −$0.44 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.14.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.49n/a
FY2024−$0.76n/a
FY2023−$0.74n/a
FY2022−$0.65n/a
FY2021−$0.52n/a
FY2020−$0.41n/a
FY2019−$0.43−295%
FY2018$0.22n/a
FY2017−$0.49n/a
FY2016−$0.76n/a
FY2015−$0.88n/a
FY2014−$0.78n/a
FY2013−$1.33n/a
FY2012−$0.72n/a
FY2011−$1.06n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.14n/a−$0.44
Q1 FY26−$0.08n/a−$0.42
Q4 FY25−$0.09n/a−$0.49
Q3 FY25−$0.13n/a−$0.59
Q2 FY25−$0.12n/a−$0.64
Q1 FY25−$0.15n/a−$0.72
Q4 FY24−$0.19n/a−$0.76
Q3 FY24−$0.18n/a−$0.73
Q2 FY24−$0.20n/a−$0.79
Q1 FY24−$0.19n/a−$0.74
Q4 FY23−$0.16n/a−$0.74
Q3 FY23−$0.24n/a−$0.76

Against its peers

Companies in Drug Manufacturers - General nearest Galectin Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
GALTGalectin Therapeutics−$0.44
ARVNArvinas$0.16
NATRNatures Sunshine Products$1.01+36% a year
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
AMPHAmphastar Pharmaceuticals$1.70−36% a year
OMEROmeros$1.52
Peer median$0.97

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Galectin Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.